Fresenius Medical Care AG (NYSE:FMS)’s share price hit a new 52-week high on Tuesday . The company traded as high as $47.52 and last traded at $47.36, with a volume of 214,306 shares trading hands. The stock had previously closed at $45.95.

Several equities analysts recently weighed in on the stock. Jefferies Group upgraded shares of Fresenius Medical Care AG from an “underperform” rating to a “hold” rating in a report on Friday, July 8th. Royal Bank Of Canada restated a “hold” rating on shares of Fresenius Medical Care AG in a report on Tuesday, May 24th. Sanford C. Bernstein assumed coverage on shares of Fresenius Medical Care AG in a report on Monday, April 11th. They set an “outperform” rating on the stock. DZ Bank AG restated a “sell” rating on shares of Fresenius Medical Care AG in a report on Tuesday, May 10th. Finally, Berenberg Bank restated a “buy” rating on shares of Fresenius Medical Care AG in a report on Tuesday. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $42.50.

The company has a 50-day moving average price of $43.93 and a 200 day moving average price of $43.22. The stock has a market cap of $29.00 billion and a PE ratio of 26.29.

Fresenius Medical Care AG (NYSE:FMS) last released its quarterly earnings results on Tuesday, August 2nd. The company reported $0.96 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.92 by $0.04. The firm had revenue of $4.42 billion for the quarter, compared to analyst estimates of $4.54 billion. Equities research analysts expect that Fresenius Medical Care AG will post $2.03 earnings per share for the current fiscal year.

A number of hedge funds and institutional investors recently added to or reduced their stakes in FMS. Morgan Stanley raised its position in Fresenius Medical Care AG by 20.5% in the fourth quarter. Morgan Stanley now owns 685,338 shares of the company’s stock valued at $28,675,000 after buying an additional 116,653 shares in the last quarter. WBI Investments Inc. bought a new position in Fresenius Medical Care AG during the fourth quarter valued at $2,249,000. Bank of Montreal Can raised its position in Fresenius Medical Care AG by 60.0% in the fourth quarter. Bank of Montreal Can now owns 56,700 shares of the company’s stock valued at $2,373,000 after buying an additional 21,264 shares in the last quarter. US Bancorp DE raised its position in Fresenius Medical Care AG by 4.0% in the fourth quarter. US Bancorp DE now owns 274,935 shares of the company’s stock valued at $11,503,000 after buying an additional 10,479 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Fresenius Medical Care AG by 3.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 107,376 shares of the company’s stock valued at $4,493,000 after buying an additional 3,694 shares in the last quarter.

Fresenius Medical Care AG & Co KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Company operates through four segments: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.